A new observational analysis from Rutgers University reports a substantial weakening of the association between impulsive traits and violent behaviour among individuals using glucagon-like peptide-1 receptor agonists, compared to non-users. This finding emerges from examination of adults with documented impulsivity and aggression histories, providing preliminary evidence for a potential neurobiological connection.
GLP-1 receptor agonists—medications including Ozempic and Wegovy—exert effects across brain regions critical to impulse regulation, with demonstrated activity in the prefrontal cortex at 95%, ventral tegmentum at 88%, and nucleus accumbens at 82%. Despite the compelling preliminary association, researchers stress that no causal relationship has been established. Off-label use for behavioural indications remains unsupported, and the team calls for rigorous randomised controlled trials before any clinical translation. Current evidence-based approval remains limited to diabetes and weight management applications.
Read the full article on GMJ Newsroom.
Was this article helpful?
GMJ Brief · Key Finding
📰 Read the full article: GLP-1 Drugs Linked to Lower Violent Behaviour in Rutgers Study →
